Diabetes Clinical Trials Market Report Scope and Overview:

The Diabetes Clinical Trials Market was valued at USD 5.25 Billion in 2025 and is projected to reach USD 11.18 Billion by 2035, growing at a CAGR of 7.85% during the forecast period.

The Diabetes Clinical Trials Market continues to expand as sponsors advance an extensive pipeline of oral and injectable glucose-lowering, weight-management, and disease-modifying candidates through late-stage development. Rising global prevalence of Type 2 diabetes, growing regulatory interest in disease-modifying Type 1 diabetes therapies, and sustained payer scrutiny of comparative efficacy data are pushing sponsors toward larger, longer, and more biomarker-intensive trial designs. Contract research organizations are responding by expanding laboratory, site-network, and decentralized data capture capability tailored to metabolic disease populations, while academic and government-funded programs continue contributing early-phase and mechanistic studies. Growing sponsor preference for connected, research-ready site networks is also shortening study start-up timelines across multi-country diabetes programs.

⮞June 2026: The American Diabetes Association presented Phase II results for the investigational oral GLP-1 candidate elecoglipron from the SOLSTICE and VISTA studies, reporting improvements in glycemic control and weight-related measures. The findings illustrate continued expansion of the early-stage oral diabetes therapeutic pipeline.

U.S. Diabetes Clinical Trials Market Outlook

The U.S. Diabetes Clinical Trials Market was valued at approximately USD 2.36 Billion in 2025 and is projected to reach USD 5.14 Billion by 2035, expanding at a CAGR of 8.10% over the forecast period.

Demand across the United States continued to be shaped by a dense concentration of sponsors advancing GLP-1, dual-agonist, and disease-modifying diabetes candidates, alongside a large base of academic medical centers and specialty metabolic research sites. Sustained commercial payer demand for comparative cardiometabolic outcome data continued to shape protocol design across late-stage U.S. diabetes programs. Contract research organizations serving the U.S. Diabetes Clinical Trials Market continued expanding central laboratory, biomarker, and connected site-network capability, while obesity and metabolic-focused site networks continued broadening recruitment reach for overlapping diabetes and weight-management programs across the country.

⮞February 2026: Eli Lilly reported results from the 1,698-participant ACHIEVE-3 Phase III trial, in which oral orforglipron demonstrated greater A1C reduction and weight loss than oral semaglutide in adults with Type 2 diabetes inadequately controlled on metformin, highlighting U.S. sponsor investment in active-comparator metabolic trials.

By Phase: Phase III Leads, Phase II Grows Fastest

The Phase III segment dominated the Diabetes Clinical Trials Market because late-stage cardiometabolic outcome studies require large, long-duration patient cohorts to satisfy regulatory and payer expectations for comparative efficacy and safety evidence. Sponsors advancing GLP-1 and dual-agonist candidates toward approval continued concentrating budget and site capacity in this phase, reinforcing its share of overall trial activity. The scale of these programs, often spanning dozens of countries and thousands of participants, continues to anchor the large majority of total diabetes trial spending within this single phase of development.

The Phase II segment is growing fastest as an expanding pool of oral small molecule and disease-modifying candidates advances from early proof-of-concept work toward larger dose-ranging studies. Sponsors are increasingly front-loading biomarker and continuous glucose monitoring endpoints into this phase to de-risk subsequent Phase III investment decisions. This shift is encouraging contract research organizations to build dedicated early-phase metabolic units capable of generating the detailed dose-response data that later-stage programs increasingly depend on.

⮞November 2025: Novo Nordisk announced positive Phase II results for investigational amycretin in Type 2 diabetes, reporting weight loss of up to 14.5% at 36 weeks and significant HbA1c improvements. The dose-finding evidence supports continued investment in mid-stage dual-pathway metabolic candidates.

By Study Design: Interventional Trials Lead, Observational Studies Grow Fastest

The Interventional segment dominated the Diabetes Clinical Trials Market as regulatory approval of new glucose-lowering and weight-management therapies continues to depend on controlled, randomized evidence rather than observational data alone. Sponsors advancing novel mechanisms toward approval default to interventional designs to generate the primary efficacy evidence regulators require, and this dependence extends across nearly every late-stage glucose-lowering and weight-management program currently active worldwide. Investigator-initiated interventional work on dosing regimens and combination therapy further reinforces the segment's lead across both originator and generic sponsor programs.

The Observational segment is the fastest growing as payers and health systems increasingly request real-world comparative effectiveness and long-term cardiometabolic outcome data following approval. Growing registry-based research into diabetes complications is further widening the addressable scope for observational study designs, with sponsors increasingly commissioning post-approval registries to track long-term renal, cardiovascular, and retinal outcomes across broader patient populations than pre-approval trials could capture. These registries are also helping sponsors build the long-term safety record that payers now expect.

⮞June 2026: Dexcom published results from its CONNECT randomized controlled trial, reporting that continuous glucose monitoring with Dexcom G7 improved HbA1c and time-in-range outcomes in adults with Type 2 diabetes who were not using insulin, demonstrating the role of device-derived endpoints in interventional diabetes research.

By Indication: Type 2 Diabetes Mellitus Dominates, Type 1 Diabetes Mellitus Grows Fastest

The Type 2 Diabetes Mellitus segment dominated the Diabetes Clinical Trials Market, reflecting the condition's substantially larger global patient population and the correspondingly deep pipeline of oral and injectable glucose-lowering and weight-management candidates in active development across pharmaceutical and biopharmaceutical sponsors. The large size of this patient population allows sponsors to run large, statistically well-powered comparative trials that would be far harder to recruit for a rarer indication, further cementing the segment's position at the center of the overall trial pipeline.

The Type 1 Diabetes Mellitus segment is the fastest growing as disease-modifying and immune-tolerance candidates advance toward regulatory review, supported by expanding pediatric and adolescent trial populations. Growing regulatory willingness to expand priority review pathways for earlier-stage disease is further accelerating trial activity in this indication, as sponsors increasingly target at-risk children identified through autoantibody screening programs before clinical onset of the disease, a strategy that requires substantially more specialized screening and recruitment infrastructure than conventional Type 2 diabetes studies.

⮞June 2025: Vertex Pharmaceuticals presented Phase I/II zimislecel results in Type 1 diabetes, reporting that 10 of 12 full-dose participants with at least one year of follow-up were insulin-free at month 12. The investigational cell-therapy findings underline increasing clinical development activity in disease-modifying approaches.

By Service: Laboratory Services Lead, Data Management and Biostatistics Grow Fastest

The Laboratory Services segment dominated the Diabetes Clinical Trials Market, supported by the central role of glycemic, lipid, and biomarker testing in nearly every diabetes trial protocol. Sponsors continue depending on central laboratory partners capable of standardizing assay methodology across large, multi-country metabolic disease study populations, since inconsistent assay calibration across sites can meaningfully distort comparative efficacy readouts. Sponsors therefore treat central laboratory selection as one of the more consequential early-stage operational decisions in any multi-country diabetes program, often locking in a single provider for the full duration of a pivotal study.

The Data Management and Biostatistics segment is the fastest growing as continuous glucose monitoring and other high-frequency digital endpoints generate substantially larger datasets than conventional visit-based measurements. Sponsors are increasingly routing this growing data volume to specialized statistical and data management partners capable of applying novel time-in-range and glycemic-variability analytics that conventional biostatistics teams were not originally built to handle, a gap that continues to widen as digital endpoints proliferate across more trial protocols.

⮞March 2025: IQVIA Laboratories launched Site Lab Navigator with electronic requisitions, real-time specimen tracking and automated data validation for clinical trial laboratories. Although applicable across therapeutic areas, the platform can support multi-site diabetes studies requiring consistent biomarker testing and sample management.

By Sponsor: Pharmaceutical and Biopharmaceutical Companies Lead, Contract Research Organizations Grow Fastest

The Pharmaceutical and Biopharmaceutical Companies segment dominated the Diabetes Clinical Trials Market as originator sponsors with novel glucose-lowering and weight-management pipelines continue to fund the large majority of late-stage trial activity, reflecting the scale of investment required to advance a candidate through global regulatory review across dozens of countries and multiple patient subpopulations simultaneously, a burden few organizations outside large originator companies can comfortably absorb without substantial external financing or a development partnership with a larger, better-capitalized pharmaceutical partner.

The Contract Research Organizations segment is the fastest growing as sponsors increasingly outsource site management, laboratory, and data operations to specialized partners rather than maintaining comparable capability internally. Expanding connected site-network models are further reinforcing this shift toward outsourced trial execution, as sponsors find that renting research-ready infrastructure is faster and less capital-intensive than building it themselves, particularly for mid-sized sponsors without an already established in-house site network or a dedicated, fully staffed metabolic disease trial operations team of their own.

⮞September 2025: IQVIA launched its AI-enabled Clinical Trial Financial Suite, integrating site-payment, budgeting and contracting workflows for clinical research programs. The CRO's investment demonstrates how outsourced trial providers are broadening technology infrastructure that can also support large, multi-country diabetes trials.

Regional Analysis

North America Diabetes Clinical Trials Market Insights

North America dominated the Diabetes Clinical Trials Market with the largest revenue share of approximately 48.60% in 2025, supported by the region's concentration of originator biopharmaceutical sponsors, deep academic medical center infrastructure, and an established base of contract research organizations offering integrated laboratory and site-network capability for large cardiometabolic outcome studies. The region's regulatory agencies also maintain some of the most well-established priority review pathways for metabolic disease candidates worldwide, which continues to draw sponsors toward early regional trial activation. Deep capital markets access for emerging biotechs further reinforces the region as a preferred launch point for novel metabolic disease programs.

The United States accounted for the substantial majority of regional revenue, anchored by a dense concentration of sponsors advancing GLP-1 and disease-modifying diabetes candidates through late-stage development. Canada continued contributing a smaller but steady share, supported by specialized metabolic research sites serving cross-border sponsor programs and a regulatory framework that allows many study protocols to be harmonized directly with the country's larger neighbor.

⮞March 2026: Eli Lilly announced that its investigational triple agonist retatrutide met primary and key secondary endpoints in the Phase III TRANSCEND-T2D-1 trial for adults with Type 2 diabetes. The U.S.-headquartered sponsor reported average HbA1c reductions of up to 2.0% after 40 weeks.

Europe Diabetes Clinical Trials Market Insights

Europe held a meaningful share of global revenue, supported by established academic diabetes research networks, harmonized regulatory review across the region, and a long-standing base of specialized metabolic research institutes that originator sponsors continue to rely on for early-phase and mechanistic studies. Coordinated multi-country regulatory review under a single regional framework continues to make the region an efficient venue for early feasibility and proof-of-concept metabolic studies, allowing sponsors to generate comparable data across several national healthcare systems within a single coordinated submission process.

Germany continued to lead regional demand at roughly 23.70% of European revenue, supported by its concentration of academic metabolic research institutes, while the United Kingdom and France continued contributing significant site capacity for late-stage cardiometabolic outcome studies. Scandinavian countries also continued to play an outsized role given their strong national diabetes registries and long patient-follow-up traditions, which sponsors increasingly tap for supplementary long-term safety and outcomes evidence.

⮞January 2025: The European Medicines Agency completed the transition requiring all ongoing EU clinical trials to operate under the Clinical Trials Regulation and Clinical Trials Information System. This harmonized regulatory framework applies to multinational diabetes trials alongside other therapeutic research programs.

Asia Pacific Diabetes Clinical Trials Market Insights

Asia Pacific is advancing at the fastest pace, growing at a CAGR of approximately 9.60% from 2026 to 2035, driven by the region's exceptionally large and treatment-naive diabetes patient population, lower-cost trial execution, and rising sponsor confidence in the region's regulatory and site-quality infrastructure. Multinational sponsors are increasingly designating regional sites as primary rather than supplementary recruitment sources for pivotal global trials, a shift that was uncommon for metabolic disease programs only a decade earlier and reflects accumulated confidence built through years of successful regional inspections.

India held a substantial share of regional revenue, supported by its large pool of treatment-naive Type 2 diabetes patients and an expanding base of research-ready trial sites, while China and Japan continued contributing significant site capacity for multinational sponsor programs. South Korea also continued strengthening its position through government-backed investment in clinical trial infrastructure and digital health monitoring capability, helping the country attract a growing share of complex, technology-intensive diabetes study protocols.

⮞September 2026: India's Indian Council of Medical Research selected a multicentre randomized RESTORE-DFU trial evaluating regenerative and oxygen-based approaches for diabetic foot ulcers among its clinical-care research proposals, illustrating expansion of investigator-led diabetes-complication trials in the country.

MEA and Latin America Diabetes Clinical Trials Market Insights

The Middle East and Africa and Latin America both showed steady growth, driven by rising diabetes prevalence linked to urbanization and dietary shift, expanding clinical research infrastructure, and growing sponsor interest in diversifying trial populations beyond traditional research hubs. Government-backed investment in both regions continues to lower the barrier for sponsors evaluating new trial locations outside established markets, particularly for sponsors seeking genetically and environmentally diverse patient populations for global registration programs that regulators increasingly expect to reflect broader real-world demographic diversity.

Saudi Arabia led Middle East and Africa demand, supported by sustained government investment in clinical research infrastructure, while Brazil led Latin America, benefiting from an established base of academic metabolic research centers and a large, genetically diverse patient population. South Africa and Mexico continued contributing secondary capacity within their respective regions, serving a mix of domestic and multinational sponsor programs that increasingly view both countries as credible secondary recruitment markets.

⮞October 2026: Saudi Arabia's Food and Drug Authority listed the ongoing ACHIEVE-RAM Phase IIIb trial of orforglipron in adults with Type 2 diabetes observing Ramadan, with sites in Riyadh, Dammam and Jeddah. The listing illustrates the region's contribution to population-specific metabolic trial protocols.

Market Dynamics

Growth Drivers: Expanding Late-Stage Pipeline and Rising Metabolic Disease Prevalence

The industry is driven by an extensive late-stage pipeline of oral and injectable glucose-lowering and weight-management candidates, as sponsors race to differentiate efficacy, tolerability, and dosing convenience ahead of an increasingly crowded competitive landscape across Type 2 diabetes and adjacent metabolic indications. This competitive pressure continues to push sponsors toward larger, more data-rich trial designs intended to establish a clear clinical edge over already-approved therapies, which in turn sustains elevated overall trial volume across the industry.

Rising global prevalence of Type 2 diabetes, linked to aging populations and shifting dietary patterns, continues supporting sustained trial volume, as sponsors seek to capture a growing and increasingly treatment-eligible patient population across both developed and emerging healthcare markets worldwide. This expanding patient base also gives sponsors a wider pool from which to recruit for the large, long-duration outcome studies that regulators increasingly expect before approving new therapies, reinforcing demand for trial infrastructure capable of operating at this growing scale.

⮞February 2026: Novo Nordisk announced Phase III REIMAGINE 2 findings for CagriSema in adults with Type 2 diabetes, reporting HbA1c reductions of up to 1.91 percentage points and weight loss of up to 14.2%. The results highlight continued demand for large pivotal trials of combination metabolic therapies.

Restraints: Patient Recruitment Complexity and Comparator Trial Costs

Persistent difficulty recruiting treatment-naive or specific-subtype diabetes patients for long-duration cardiometabolic outcome studies continues posing a restraint, particularly for trials requiring extended washout periods or exclusion of common comorbid conditions that narrow the eligible patient pool. Sponsors increasingly compete for the same limited pool of treatment-naive patients, which can extend recruitment timelines well beyond original study planning assumptions and push back expected regulatory submission dates for an entire development program across every single participating country.

Rising costs associated with active-comparator and long-duration outcome trial designs continue posing a restraint, as regulators and payers increasingly expect head-to-head efficacy data against already-approved therapies rather than placebo-controlled evidence alone, extending both trial duration and total program cost. Sourcing and supplying an active comparator across dozens of countries adds further logistical and regulatory complexity that smaller sponsors in particular can struggle to manage without a well-resourced contract research partner handling comparator drug supply chain logistics.

Opportunities: Disease-Modifying Type 1 Therapies and Digital Endpoint Adoption

Rising sponsor investment in disease-modifying and immune-tolerance therapies for Type 1 diabetes represents a significant opportunity, particularly as regulators show growing willingness to expand priority review pathways for earlier-stage pediatric and adolescent disease populations. Contract research organizations that build dedicated pediatric and autoantibody-screening capability stand to capture a growing share of this still-underserved segment of trial activity, which remains comparatively less crowded than mainstream Type 2 diabetes development and commands a correspondingly stronger pricing position.

Expanding adoption of continuous glucose monitoring and other digital endpoints offers a second substantial opportunity, as sponsors and contract research partners able to manage high-frequency data streams gain a meaningful advantage in designing shorter, more sensitive trial protocols. Partners that invest early in the analytics capability these endpoints require are increasingly winning preferred-provider status with sponsors running competitive metabolic disease programs, a durable advantage that is difficult for late-moving competitors to replicate quickly once sponsor relationships are established.

⮞March 2026: Continuity Biosciences and Breakthrough T1D announced a collaboration to advance the NICHE cell-therapy platform toward a planned first-in-human Phase I/IIa study in Type 1 diabetes. The partnership supports clinical translation of approaches designed to protect transplanted insulin-producing cells.

Diabetes Clinical Trials Market key players are:

• IQVIA Inc.

• ICON plc

• Labcorp Drug Development

• Parexel International Corporation

• Syneos Health

• Fortrea Inc.

• Medpace Holdings, Inc.

• WuXi Clinical Development

• Worldwide Clinical Trials

• ProSciento, Inc.

• Profil Institut fur Stoffwechselforschung GmbH

• Celerion, Inc.

• Altasciences

• Medidata Solutions, Inc.

• Eurofins Central Laboratory

Diabetes Clinical Trials Market Report Scope: